Financings in Brief: Integ
This article was originally published in The Gray Sheet
Executive Summary
Integ: Plans to go public with an offering of 3.5 mil. shares of common stock at an expected price of $12 to $14 per share, according to a registration statement filed May 2 with SEC. The St. Paul, Minnesota-based firm expects to net approximately $35.9 mil. from the offering. Proceeds could reach $41.3 mil. if an over-allotment option granted to underwriters Piper Jaffray and Montgomery Securities is exercised in full. Funds will go toward continued development, testing and clinical trials of Integ's Lifeguide System glucose monitor, for which the firm intends to submit a 510(k) to FDA during the first half of 1997. Integ's development timeline for the monitor, which measures glucose present in interstitial fluid rather than blood, has been pushed back from the schedule outlined by the company at an investment conference in January. At that time, Integ was planning on a third quarter 1996 510(k) submission ("The Gray Sheet" Jan. 22, p. 9)...
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.